UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Oral chemotherapy: rationale and future directions

Journal of clinical oncology, 1998-07, Vol.16 (7), p.2557-2567

1998

Volltextzugriff (PDF)

Implementation of a Blood Management Program at a Tertiary Care Hospital: Effect on Transfusion Practices and Clinical Outcomes Among Patients Undergoing Surgery

Annals of surgery, 2019-06, Vol.269 (6), p.1073

2019

Volltextzugriff (PDF)

Patient Blood Management Program Improves Blood Use and Clinical Outcomes in Orthopedic Surgery

Anesthesiology (Philadelphia), 2018-12, Vol.129 (6), p.1082-1091

2018

Volltextzugriff (PDF)

Rrp6 Moonlights in an RNA Exosome-Independent Manner to Promote Cell Survival and Gene Expression during Stress

Cell reports (Cambridge), 2020-06, Vol.31 (10), p.107754-107754, Article 107754

2020

Volltextzugriff (PDF)

A Restrictive Hemoglobin Transfusion Threshold of Less Than 7 g/dL Decreases Blood Utilization Without Compromising Outcomes in Patients With Hip Fractures

Journal of the American Academy of Orthopaedic Surgeons, 2019-12, Vol.27 (23), p.887

2019

Volltextzugriff (PDF)

29 A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors

European journal of cancer (1990), 2012-11, Vol.48, p.12-12

2012

Volltextzugriff (PDF)

Discharge Hemoglobin Level and 30-Day Readmission Rates After Coronary Artery Bypass Surgery

Anesthesia and analgesia, 2019-02, Vol.128 (2), p.342-348

2019

Volltextzugriff (PDF)

A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

Hematological oncology, 2017-06, Vol.35 (S2), p.263-265

2017

Volltextzugriff (PDF)

Blood utilization and mortality in victims of gun violence

Transfusion (Philadelphia, Pa.), 2018-10, Vol.58 (10), p.2326-2334

2018

Volltextzugriff (PDF)

On‐label compared to off‐label four‐factor prothrombin complex concentrate use: a retrospective, observational study

Transfusion (Philadelphia, Pa.), 2019-08, Vol.59 (8), p.2678-2684

2019

Volltextzugriff (PDF)

One‐unit compared to two‐unit platelet transfusions for adult oncology outpatients

Vox sanguinis, 2019-07, Vol.114 (5), p.517-522

2019

Volltextzugriff (PDF)

1017O NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma

Annals of oncology, 2023-10, Vol.34, p.S619-S619

2023

Volltextzugriff (PDF)

Lymphomas in the immunocompromised patient

Seminars in oncology, 1998-08, Vol.25 (4), p.492-502

1998

Volltextzugriff (PDF)

A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

Cancer chemotherapy and pharmacology, 1999, Vol.43 (5), p.385-388

1999

Volltextzugriff (PDF)

A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2502-2502

2010

Volltextzugriff (PDF)

A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3528-3528

2007

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Novel Oral Cell-Cycle Inhibitor Ro 31-7453 in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2004-08, Vol.22 (16), p.3366-3374

2004

Volltextzugriff (PDF)

A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors

Clinical cancer research, 2004-07, Vol.10 (13), p.4374-4382

2004

Volltextzugriff (PDF)

A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2028-2028

2006

Volltextzugriff (PDF)

Implementation of a Blood Management Program at a Tertiary Care Hospital: Effect on Transfusion Practices and Clinical Outcomes Among Patients Undergoing Surgery

Annals of surgery, 2017-11

2017

Volltextzugriff (PDF)

Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.778-778

2005

Volltextzugriff (PDF)

A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer

Cancer chemotherapy and pharmacology, 2004-11, Vol.54 (5), p.377-384

2004

Volltextzugriff (PDF)

Lymphomas in the immunocompromised patient : Lymphomas

Seminars in oncology, 1998, Vol.25 (4), p.492-502

1998

Volltextzugriff (PDF)

281 POSTER A phase I study of R547, a novel cyclin dependent kinase inhibitor, in patients (pts) with advanced cancer: preliminary results

European journal of cancer supplements, 2006-11, Vol.4 (12), p.89-89

2006

Volltextzugriff (PDF)

Rationale for phase I study of UFT plus leucovorin and oral JM-216

Oncology (Williston Park, N.Y.), 1997-09, Vol.11 (9 Suppl 10), p.26

1997

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(63)
Buchkapitel
(1)

Sprache

Englisch
(64)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(36)
Humans
(33)
Female
(21)
Adult
(20)
Male
(18)
Middle Aged
(16)
Aged
(15)
Oncology
(11)
Biological And Medical Sciences
(9)
Neurosciences & Neurology
(9)
Chronic Pain
(7)
Medical Sciences
(7)
Neurosciences
(7)
Retrospective Studies
(7)
Back Pain
(6)
Clinical Neurology
(6)
Aged, 80 And Over
(5)
Antineoplastic Agents - Pharmacokinetics
(5)
Chronic Low Back Pain
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral chemotherapy: rationale and future directions

Implementation of a Blood Management Program at a Tertiary Care Hospital: Effect on Transfusion Practices and Clinical Outcomes Among Patients Undergoing Surgery

Patient Blood Management Program Improves Blood Use and Clinical Outcomes in Orthopedic Surgery

Rrp6 Moonlights in an RNA Exosome-Independent Manner to Promote Cell Survival and Gene Expression during Stress

A Restrictive Hemoglobin Transfusion Threshold of Less Than 7 g/dL Decreases Blood Utilization Without Compromising Outcomes in Patients With Hip Fractures

29 A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors

Discharge Hemoglobin Level and 30-Day Readmission Rates After Coronary Artery Bypass Surgery

A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

Blood utilization and mortality in victims of gun violence

On‐label compared to off‐label four‐factor prothrombin complex concentrate use: a retrospective, observational study

One‐unit compared to two‐unit platelet transfusions for adult oncology outpatients

1017O NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma

Lymphomas in the immunocompromised patient

A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors

A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs)

Phase I and Pharmacokinetic Study of the Novel Oral Cell-Cycle Inhibitor Ro 31-7453 in Patients With Advanced Solid Tumors

A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors

A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies

Implementation of a Blood Management Program at a Tertiary Care Hospital: Effect on Transfusion Practices and Clinical Outcomes Among Patients Undergoing Surgery

Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer

A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer

Lymphomas in the immunocompromised patient : Lymphomas

281 POSTER A phase I study of R547, a novel cyclin dependent kinase inhibitor, in patients (pts) with advanced cancer: preliminary results

Rationale for phase I study of UFT plus leucovorin and oral JM-216

Suchergebnisse filtern